Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Uterine Corpus Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 147 active trials
4 drugs · 55 active trials
Data updated 4 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Lifileucel | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 29, 2024 |
| Neratinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 7, 2023 |
| Nilotinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 7, 2023 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Panitumumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 7, 2023 |
| Prexasertib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 29, 2022 |
| Rezatapopt | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 29, 2020 |
| Sotorasib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 7, 2023 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Tazemetostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2019 |
| Trastuzumab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Rucaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Jun 29, 2018 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2011-02 |
| Ridaforolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2005-08 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2000-09 |
| Aldesleukin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1997-10 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-09 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-03 |
| Exemestane | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-03 |
| Futibatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Sep 30, 2021 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2000-08 |
| Lurbinectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 6, 2016 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-01 |
| Pemigatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 27, 2015 |
| Pilaralisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-09 |
| Retifanlimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 27, 2015 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-02 |
| Tislelizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 1, 2021 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-03 |
| Alisertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-08 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-07 |
| Apitolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-12 |
| Dactolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-03 |
| Dexamethasone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-04 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-01 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-11 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 20, 2018 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-10 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 9, 2003 |
| Aromatase Inhibitor | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 10, 2019 |
| Cobimetinib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 14, 2023 |
| Elimusertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 25, 2021 |
| Immunotherapy | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 16, 2025 |
| Mercaptopurine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2026 |
| Mitomycin | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 21, 2020 |
| Ruxolitinib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 15, 2017 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 31, 2021 |
| Eribulin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 14, 2006 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.